The present invention relates to a pharmaceutical composition comprising an anti-VEGFR-2 antibody. The pharmaceutical composition of the present invention can treat, prevent, or alleviate cerebral edema. For patients who are administered a steroid agent to treat, prevent, or alleviate cerebral edema, the pharmaceutical composition of the present invention also allows a reduction in the administration dosage and/or time of the steroid agent. In addition, the pharmaceutical composition of the present invention can significantly prolong a survival time of a patient suffering from cerebral edema or glioblastoma.
